Vigil Neuroscience to Present at Upcoming Investor Conferences
Vigil Neuroscience (Nasdaq: VIGL), a clinical-stage biotech company focusing on microglia-based treatments for neurodegenerative diseases, has announced its participation in two major investor conferences. The company will present at the Stifel 2024 Healthcare Conference on November 18th at 4:45 p.m. ET and the Jefferies London Healthcare Conference on November 20th at 8:30 a.m. GMT. Both presentations will be in a fireside chat format. The webcasts will be accessible through the company's website's Investors section and will remain available for approximately 90 days after the presentations.
Vigil Neuroscience (Nasdaq: VIGL), un'azienda biotech in fase clinica focalizzata su trattamenti basati sulle microglia per le malattie neurodegenerative, ha annunciato la sua partecipazione a due importanti conferenze per investitori. L'azienda presenterà alla Stifel 2024 Healthcare Conference il 18 novembre alle 16:45 ET e alla Jefferies London Healthcare Conference il 20 novembre alle 8:30 GMT. Entrambe le presentazioni si svolgeranno in formato chat informale. Le trasmissioni in web streaming saranno accessibili attraverso la sezione Investitori del sito web dell'azienda e rimarranno disponibili per circa 90 giorni dopo le presentazioni.
Vigil Neuroscience (Nasdaq: VIGL), una empresa biotecnológica en etapa clínica enfocada en tratamientos basados en microglía para enfermedades neurodegenerativas, ha anunciado su participación en dos importantes conferencias para inversionistas. La empresa presentará en la Stifel 2024 Healthcare Conference el 18 de noviembre a las 4:45 p.m. ET y en la Jefferies London Healthcare Conference el 20 de noviembre a las 8:30 a.m. GMT. Ambas presentaciones se llevarán a cabo en un formato de charla informal. Las transmisiones web estarán disponibles a través de la sección de Inversores del sitio web de la empresa y permanecerán accesibles durante aproximadamente 90 días después de las presentaciones.
Vigil Neuroscience (Nasdaq: VIGL)는 신경퇴행성 질환에 대한 미세아교세포 기반 치료에 중점을 둔 임상 단계의 생명공학 회사로, 두 개의 주요 투자자 회의에 참여한다고 발표했습니다. 이 회사는 Stifel 2024 Healthcare Conference에서 11월 18일 오후 4시 45분 ET에 발표하며, Jefferies London Healthcare Conference에서는 11월 20일 오전 8시 30분 GMT에 발표할 예정입니다. 두 발표 모두 캠프파이어 채팅 형식으로 진행됩니다. 웹캐스트는 회사 웹사이트의 투자자 섹션을 통해 접근 가능하며 발표 후 약 90일 동안 유지될 것입니다.
Vigil Neuroscience (Nasdaq: VIGL), une entreprise biotechnologique en phase clinique axée sur des traitements basés sur les microglies pour les maladies neurodégénératives, a annoncé sa participation à deux grandes conférences pour investisseurs. L'entreprise présentera lors de la Stifel 2024 Healthcare Conference le 18 novembre à 16h45 ET et lors de la Jefferies London Healthcare Conference le 20 novembre à 8h30 GMT. Les deux présentations se dérouleront sous forme de discussion informelle. Les diffusions en direct seront accessibles via la section Investisseurs du site web de l'entreprise et resteront disponibles pendant environ 90 jours après les présentations.
Vigil Neuroscience (Nasdaq: VIGL), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf mikrogliabasierte Behandlungen für neurodegenerative Erkrankungen konzentriert, hat seine Teilnahme an zwei wichtigen Anlegerkonferenzen bekannt gegeben. Das Unternehmen wird am 18. November um 16:45 Uhr ET auf der Stifel 2024 Healthcare Conference und am 20. November um 8:30 Uhr GMT auf der Jefferies London Healthcare Conference präsentieren. Beide Präsentationen werden im Format eines informellen Gesprächs stattfinden. Die Webcasts werden über den Bereich Investoren der Unternehmenswebsite zugänglich sein und etwa 90 Tage nach den Präsentationen verfügbar bleiben.
- None.
- None.
WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will be presenting at the following conferences in November:
Stifel 2024 Healthcare Conference
Format: Fireside Chat
Date/Time: Monday, November 18th at 4:45 p.m. ET
Jefferies London Healthcare Conference
Format: Fireside Chat
Date/Time: Wednesday, November 20th at 8:30 a.m. GMT
The webcasts will also be available on the Company’s website in the “Investors” section under “Events & Presentations.” Archived webcasts will be available for approximately 90 days following the presentation.
About Vigil Neuroscience
Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Vigil is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Iluzanebart, Vigil’s lead clinical candidate, is a fully human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 (TREM2) in people with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. Vigil is also developing VG-3927, a novel small molecule TREM2 agonist, to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease (AD) patients, including some who carry TREM2 and other disease-associated variants.
Internet Posting of Information
Vigil Neuroscience routinely posts information that may be important to investors in the “Investors” section of its website at https://www.vigilneuro.com. The company encourages investors and potential investors to consult our website regularly for important information about Vigil Neuroscience.
Investor Contact:
Leah Gibson
Vice President, Investor Relations & Corporate Communications
Vigil Neuroscience, Inc.
lgibson@vigilneuro.com
Media Contact:
Megan McGrath
CTD Comms, LLC
megan@ctdcomms.com
FAQ
When is Vigil Neuroscience (VIGL) presenting at the Stifel 2024 Healthcare Conference?
What type of presentation format will VIGL use at the November 2024 healthcare conferences?
How long will the VIGL conference webcasts be available for viewing?
What time is Vigil Neuroscience (VIGL) presenting at the Jefferies London Healthcare Conference?
